Systemic glucocorticoid use in Denmark: a population-based prevalence study

Kristina Laugesen, Jens Otto Lunde Jørgensen, Henrik Toft Sørensen, Irene Petersen, Kristina Laugesen, Jens Otto Lunde Jørgensen, Henrik Toft Sørensen, Irene Petersen

Abstract

Objectives: Glucocorticoid (GC) use is widespread and associated with many adverse effects. Thus, it is important to ascertain GC utilisation patterns. In this study, we examined the annual prevalence of prescription users and amount of use of systemic GCs.

Design: Population-wide prevalence study.

Setting: The primary healthcare and hospital sectors in Denmark from 1999 to 2015.

Results: Approximately 3% of the Danish population redeemed at least one prescription for a systemic GC annually between 1999 and 2015, with annual prevalence remaining constant over the period. However, after adjusting for age and sex, we observed a decrease in annual prevalence from 1999 to 2015, with a prevalence ratio of 0.92 (95% CI 0.91 to 0.92). Annual prevalence was highest among the elderly (7.0%-8.2% among persons 65-79 years of age and 8.4%-10% among persons 80+ years of age). Prednisolone was the most frequently redeemed systemic GC, with annual prevalence increasing from 1.4% to 2.1% during the 1999-2015 period. The amount of systemic GCs provided to the hospital sector increased from 2.3 defined daily doses (DDD)/1000 inhabitants/day in 1999 to 3.5 DDD/1000 inhabitants/day in 2015, while the amount provided to the primary healthcare sector remained constant in the range of 10-11 DDD/1000 inhabitants/day.

Conclusion: We found a high prevalence of systemic GC use of 3% with a remarkably high prevalence in elderly of up to 10%, wherefore continued awareness of its effects is mandated.

Keywords: Denmark; Drug utilisation; Glucocorticoids; Prevalence.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Annual prevalence of systemic glucocorticoid (GC) prescription users in Denmark, 1999–2015, overall and stratified by generic type. All systemic GCs (red line), prednisolone (dark blue line), betamethasone (green line), prednisone (orange line), methylprednisolone (blue line), triamcinolone (dark green line), hydrocortisone (purple line), dexamethasone (light blue line).

References

    1. Rasmussen Å. . Information on glucocorticoid package sizes and indications in Denmark [in Danish]. 2016;2015.
    1. Broersen LH, Pereira AM, Jørgensen JO, et al. . Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:2171–80. 10.1210/jc.2015-1218
    1. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. . Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013;173:743–52. 10.1001/jamainternmed.2013.122
    1. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ 2012;345:e4928 10.1136/bmj.e4928
    1. Davis JM, Maradit Kremers H, Crowson CS, et al. . Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;56:820–30. 10.1002/art.22418
    1. Christiansen CF, Christensen S, Mehnert F, et al. . Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 2009;169:1677–83. 10.1001/archinternmed.2009.297
    1. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469–74. 10.4158/EP08331.RAR
    1. Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metabolism 1984;33:521–6. 10.1016/0026-0495(84)90006-4
    1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–87. 10.1007/s001980200108
    1. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry 2012;169:491–7. 10.1176/appi.ajp.2011.11071009
    1. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology 2011;50:1982–90. 10.1093/rheumatology/ker017
    1. van Staa TP, et al. . Use of oral corticosteroids in the United Kingdom. QJM 2000;93:105–11. 10.1093/qjmed/93.2.105
    1. Overman RA, Yeh J-Y, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res 2013;65:294–8. 10.1002/acr.21796
    1. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39:22–5. 10.1177/1403494810387965
    1. Anonymous, Danish Serum Institute. Statistics on the annual sale of medicines in Denmark based on the data from the Register of Medicinal Product Statistics. 2016;2016.
    1. Kildemoes HW, Sørensen HT, Hallas J. The Danish National prescription registry. Scand J Public Health 2011;39:38–41. 10.1177/1403494810394717
    1. WHO collaborating Centre for Drug Statistics Methodology. Definition and general considerations. 2016;2017.
    1. Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc 2003;78:1564–77. 10.4065/78.12.1564
    1. Sundheds- og ældreministeriet. Healthcare in Denmark- an overview. 2016;2016.
    1. Hammer T, Nielsen KR, Munkholm P, et al. . The Faroese IBD study: incidence of inflammatory bowel diseases across 54 years of population-based data. Journal of Crohn's and Colitis 201610:934–42. 10.1093/ecco-jcc/jjw050
    1. Minichiello E, Semerano L, Boissier M-C. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2016;83:625–30. 10.1016/j.jbspin.2016.07.007
    1. Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology of chronic obstructive pulmonary disease in England: a national study of 51 804 patients. Br J Gen Pract 2010;60:277–84. 10.3399/bjgp10X514729

Source: PubMed

3
Tilaa